Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a combination of historical and untreated prospective controls - KIBB01

Next Previous
Trial Profile

An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a combination of historical and untreated prospective controls - KIBB01

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BT 101-BOOST Pharma (Primary)
  • Indications Osteogenesis imperfecta
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Acronyms BOOSTB4

Most Recent Events

  • 26 Nov 2025 New trial record
  • 31 Oct 2025 According to BOOST Pharma media release, two-year follow-up data from the landmark BOOSTB4 study has been selected for presentation by BOOST Pharma co-founder Dr. Cecilia Gotherstrom at the prestigious 15th International Conference on Osteogenesis Imperfecta (OI), taking place from October 29-31, 2025, in Hong Kong.
  • 31 Oct 2025 According to BOOST Pharma media release, this study received funding from the European Union's Horizon 2020 Research and Innovation Program and from the Swedish Research Council with Karolinska Institutet as study sponsor.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top